Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Utility of Amyloid Beta-peptide 1-40 Measurement in the Diagnosis of Alzheimer's Disease

NCT02770482 is registered in ClinicalTrials.gov with CHU de Reims as lead sponsor.

NCT NCT02770482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02770482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Utility of Amyloid Beta-peptide 1-40 Measurement in the Diagnosis of Alzheimer's Disease
Lead sponsor
CHU de Reims
Phase
Not applicable
Overall status
Completed
Start date
June 30, 2014
Completion date
March 14, 2018
Enrollment
204 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease